现代脂质三联治疗PPT课件.ppt

Cerivastatin Clinical Data Part VI Change in LDL/HDL Ratio Datapool analysis, 8 weeks 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 Baseline 0.1mg 0.2mg 0.3mg 0.4mg 0.8mg n = 459 n = 636 n = 645 n = 1072 n = 732 LDL/HDL Ratio Data on file 50 45 40 35 30 25 20 15 10 5 0 25.6 0.7 46.2 40.2 35.5 32.0 % Change in LDL/HDL Ratio Datapool analysis, 8 weeks % Change in LDL/HDL Ratio Placebo 0.1mg 0.2mg 0.3mg 0.4mg 0.8mg Data on file 现代脂质三联治疗 Introduction Part I Efficacy - The Power to Reach Target Key Factor: + Differentiators: LDL Reduction TG HDL LDL/HDL Ratio The Lipid Triad The LDL/HDL Ratio - Our Strength, Our Story!! Clear positioning for Lipobay A new perception of efficacy Differentiation to Atorvastatin Fit with our product profile LDL HDL Additional risk factor, especially in diabetics The Lipid Triad - Overview TG The Lipid Triad The Ratio The Lipid Triad and Strategic Rationale Part II No scientific evidence Evidence contradicting this statement A marketing hypothesis to build their LDL story Creating the perception of the statin with the strongest efficacy It’s logical It’s measurable It’s practicable The Lipid Triad - The GP’s Perspective Supporting Data from Landmark Studies Part III 12 10 8 6 4 2 0 % Mortality Placebo Q1 Q2 Q3 Q4 (low HDL-increase) (high HDL-increase) 4S - Study CAD Mortality per Quartiles of Increases in HDL-Cholesterol KJEKSHUS J PEDERSEN T (unpublished) HDL Intervention Trial (VA-HIT) RUBINS HB et al. New Engl J Med 1999; 341:410 0 6 -31 -4 -35 -30 -25 -20 -15 -10 -5 0 5 10 Cholesterol LDL-C HDL-C Triglycerides Percent change compared to placebo at 1 year Secondary Prevention in 2531 menwith low HDL-C LDL-C showed a22% reduction in combined fataland non-fatal MI HDL - Cholesterol as Risk Factor for CHD LRC - CPPT (Placebo) MRFIT (usual care) Incidence rate of CHD Incid